Skip to content

Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal

Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02894112
Enrollment
30
Registered
2016-09-09
Start date
2013-04-30
Completion date
2015-12-31
Last updated
2016-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Fat Tolerance Test, Oral Glucose Tolerance Test

Keywords

endothelial dependent vasodilation, blood flow, blood glucose, triglycerides, non-fat milk, dairy

Brief summary

Epidemiological studies indicate that risk of type 2 diabetes is lower when milk is consumed in the regular diet. Milk products are unique in that they produce high insulin response despite their low glycemic index. The general aim of the proposed study is to determine the effect of fluid milk on attenuating the postprandial surge in plasma glucose and triglyceride after meals and its associated physiological mechanisms. The investigators hypothesize that the consumption of one or two servings of non-fat milk added to a standard oral glucose tolerance test (OGTT) solution or the high fat tolerance test meal will attenuate postprandial hyperglycemia and triglyceridemia. The investigators hypothesize that the postulated improvement in postprandial metabolic response due to the consumption of fluid milk will be associated with increased postprandial insulin secretion as well as insulin-mediated endothelial vasodilation and whole-limb perfusion.

Detailed description

A double blind randomized placebo-controlled crossover experimental design with six treatments will be used. A total of 30 young (20-40 year old) healthy men and women will serve as subjects. Following 2 days of physical activity and dietary control, subjects will consume a standard OGTT load or high fat tolerance load on the morning of Day 3. The solution used in the meals will be mixed with one or two servings of non-fat milk or placebo (either carbohydrate matched or total calorie matched). Before and after the test meals are consumed, blood samples will be obtained for later analysis of glucose, triglycerides, insulin, and inflammatory cytokines and brachial artery flow-mediated dilation and femoral artery vascular conductance will be measured. The present research project should provide new and clinically useful insight into the role of conventional dairy products on metabolic homeostasis. If the working hypotheses are supported, the information could be used as an initial/preliminary basis for recommendations for the consumption of fluid milk in the prevention of metabolic diseases.

Interventions

DIETARY_SUPPLEMENTnon-fat milk

1 serving of non-fat fluid milk

DIETARY_SUPPLEMENTcarbohydrate control beverage

1 serving of carbohydrate control beverage (Carbohydrate powder + water)

DIETARY_SUPPLEMENTcaloric control beverage

1 serving of caloric control beverage (carbohydrate powder + protein powder + water)

Sponsors

Dairy Research Institute
CollaboratorOTHER
University of Texas at Austin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Apparently health, sedentary. All subjects will have a BMI of 25-35 kg/m2.

Exclusion criteria

* Candidates who are taking cardiovascular-acting drugs will not be eligible for participation. Subjects with significant intima-media thickening, plaque formation, characteristics of atherosclerosis, metabolic diseases, gastrointestinal disorders, and/or renal disease will be excluded from the study. Additional

Design outcomes

Primary

MeasureTime frame
blood glucose2 hour postprandially
plasma triglyceride4 hour postprandially

Secondary

MeasureTime frame
femoral artery blood flow2-4 hour postprandially
brachial artery flow-mediated dilation2-4 hour postprandially

Other

MeasureTime frame
insulin2-4 hour postprandially
glucagon2-4 hour postprandially
GIP2-4 hour postprandially
GLP2-4 hour postprandially

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026